MSB 7.69% $1.19 mesoblast limited

The adult trial is interesting comparing Rem-L against SOC (we...

  1. 15,453 Posts.
    lightbulb Created with Sketch. 5535
    The adult trial is interesting comparing Rem-L against SOC (we know who that is ... lol)

    The other interesting comment about the adult GVHD rollout (assuming it passes or is better than SOC) is going to be handled internally by Mesoblast - no partner ? That will make a big difference to revenues not having to share revenues in this indication.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.